$NBIO SAN DIEGO, CA / ACCESSWIRE / March 24, 2021
Post# of 18193
![Avatar](/images/ProfileImages/734810790_1098_wst.png)
![](/images/icons/icon_wink.gif)
Screening to enroll patients in the trial is already underway. Those interested may review trial requirements here: https://www.clinicaltrials.gov/ct2/results?te...mp;phase=0
PTB is a natural human antibody that works by binding to Cell surface Vimentin (sometimes referred to as ectodomain vimentin, or EDV), a protein expressed on the surface of epithelial cancers. The PTB antibody is used as a targeted immunotherapy, which unlike chemotherapy, targets only the cancer cells without damaging healthy cells.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)